ライフサイエンスコーパス: postmenopausal

1 5 +/- 9.6 years, and 90.5% were women (56.9% postmenopausal).

2 ess Scale score of 9.8 (4.4), and 77.5% were postmenopausal.

3 transitional, early postmenopausal, and late postmenopausal.

4 ith a family history, and for women who were postmenopausal.

5 Most were postmenopausal (66%), parous with a first full-term preg

6 eased incidence of TNBC in premenopausal and postmenopausal African American women.

7 rican-American women, and particularly among postmenopausal African-American women.

8 an population mainly with respect to risk of postmenopausal and hormone receptor positive BC.

9 d from women of two age groups (under 27 and postmenopausal) and from two body sites with varying UV

10 efined as nonmenopausal, transitional, early postmenopausal, and late postmenopausal.

11 Additionally, among 121 patients not postmenopausal at randomisation with MAF-positive tumour

12 l, 4,534 women were premenopausal, and 6,481 postmenopausal, at the time of mammography.

13 We modeled the etiology of postmenopausal biology on ovarian cancer risk using germ

14 equol-producing ability of the individual on postmenopausal bone calcium retention.

15 Risks of postmenopausal breast and endometrial cancer related to

16 For postmenopausal breast and endometrial cancer, every 10-y

17 0.44, 95% CI:0.31-0.62, p = 9.91 x 10-8) and postmenopausal breast cancer (OR = 0.57, 95% CI: 0.46-0.

18 The reduced risk of postmenopausal breast cancer associated with genetically

19 re to ambient air pollution and incidence of postmenopausal breast cancer in European women.

20 tween ambient air pollution and incidence of postmenopausal breast cancer in European women.

21 We tested this hypothesis in a postmenopausal breast cancer model using ovariectomized,

22 ere associated with lower rates of incident, postmenopausal breast cancer over 5 y of follow-up.

23 supplement use was associated with increased postmenopausal breast cancer risk in women with high vit

24 relation between total vitamin C intake and postmenopausal breast cancer risk that deserves further

25 A decreased postmenopausal breast cancer risk was associated with cu

26 nt endocrine therapies on CVD in a cohort of postmenopausal breast cancer survivors in analyses that

27 The corresponding RRs for postmenopausal breast cancer were 0.84 (95% CI, 0.60-1.1

28 cadmium exposure is associated with risk of postmenopausal breast cancer.

29 .S. in the late 1990s for estrogen-dependent postmenopausal breast cancer.

30 ly associated with the risk of both pre- and postmenopausal breast cancer.

31 increased incidence of premenopausal but not postmenopausal breast cancer.

32 phy, and more than half of premenopausal and postmenopausal breast cancers are explained by these fac

33 enopausal and 26.2% (95% CI, 24.4%-28.0%) of postmenopausal breast cancers could potentially be avert

34 menopause account for more than one-third of postmenopausal breast cancers; therefore, a substantial

35 e, and 13 metabolites were measured in 1,298 postmenopausal cases of breast cancer and 1,524 matched

36 ium clinical supplementation trials in 2,207 postmenopausal Caucasian women.

37 ariation in 25(OH)D dose-response in healthy postmenopausal Caucasian women.

38 k of respiratory symptoms increased in early postmenopausal (coefficient, 0.40; 95% CI, 0.06-0.75) an

39 efficient, 0.40; 95% CI, 0.06-0.75) and late postmenopausal (coefficient, 0.69; 95% CI, 0.15-1.23) wo

40 negatively correlated with age, was lower in postmenopausal compared to premenopausal women and in sm

41 Even at postmenopausal concentrations, progesterone activates PR

42 Estrogen, even at postmenopausal concentrations, suppresses invasiveness o

43 of reduced endogenous estrogens and risk for postmenopausal depression have not been systematically e

44 Because tamoxifen acts as an agonist in the postmenopausal endometrium, similar to estrogen in the b

45 first-line endocrine treatment of choice for postmenopausal estrogen receptor-positive (ER(+)) breast

46 metabolic syndrome with an increased risk of postmenopausal estrogen receptor-positive breast cancer.

47 Of note, in postmenopausal female mice, ventricular repolarization w

48 A total of 254 postmenopausal female participants were included in this

49 iodontal pathogens in the oral microbiota of postmenopausal females and to explore the relationship b

50 he PVN associated with AngII hypertension in postmenopausal females compared with males.

51 A total of 1,252 postmenopausal females enrolled in the Buffalo Osteoporo

52 -year incidence of tooth loss in a cohort of postmenopausal females was examined.

53 Gender (premenopausal and postmenopausal females), age (prepubertal children), and

54 aried between oral contraceptive pill users, postmenopausal females, and females in the follicular an

55 A preventive maintenance program for postmenopausal females, particularly osteoporotic female

56 In this cohort of postmenopausal females, the data do not support an assoc

57 r the treatment of osteoporosis in males and postmenopausal females.

58 an observational cross-sectional study of 76 postmenopausal females.

59 luence the prevalence of periodontitis among postmenopausal females.

60 after a mammogram (OR, 2.64; P < .001), and postmenopausal hormone therapy (OR, 1.69; P = .002).

61 ive use, body mass index, menopausal status, postmenopausal hormone therapy use, diastolic blood pres

62 ypothesis that the cardiovascular effects of postmenopausal hormone therapy vary with the timing of t

63 ers and confounders, such as smoking status, postmenopausal hormone use, and ethnicity, was assessed.

64 t and last live birth, age at menopause, and postmenopausal hormone use.

65 much more pronounced in women who never used postmenopausal hormones.

66 investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer pati

67 tions and papillomatosis frequently found in postmenopausal human ovaries.

68 iratory symptoms increased in women becoming postmenopausal in a longitudinal population-based study.

69 In this guideline, postmenopausal includes patients with natural menopause

70 olites in a nested case-control study in 621 postmenopausal invasive breast cancer cases and 621 matc

71 e suggested that, among Hominidae, prolonged postmenopausal longevity evolved uniquely in humans [1],

72 (odds ratio, 2.40; 95% CI, 1.09-5.30), early postmenopausal (odds ratio, 2.11; 95% CI, 1.06-4.20), an

73 ds ratio, 2.11; 95% CI, 1.06-4.20), and late postmenopausal (odds ratio, 3.44; 95% CI, 1.31-9.05) at

74 Among healthy postmenopausal older women with a mean baseline serum 25

75 We enrolled men and postmenopausal or hysterectomised women (aged 18-65 year

76 e isoflavone and probiotic treatment against postmenopausal osteopenia.We used a novel red clover ext

77 ontrolled, randomized controlled trial of 78 postmenopausal osteopenic women supplemented with calciu

78 Key Clinical Points Postmenopausal Osteoporosis Fractures and osteoporosis a

79 on bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning from bisphosph

80 olled women (aged >/=55 to </=90 years) with postmenopausal osteoporosis who had taken an oral bispho

81 have potential as a therapeutic strategy for postmenopausal osteoporosis.

82 ans should follow guidelines established for postmenopausal osteoporosis.

83 bone loss in the ovariectomy mouse model of postmenopausal osteoporosis.

84 ring the 5' end of PTHLH was associated with postmenopausal osteoporosis.

85 ing the initial and subsequent management of postmenopausal osteoporotic patients.

86 ssess the changes in bone mineral density in postmenopausal osteoporotic women who transitioned betwe

87 Accordingly, among 190,325 postmenopausal participants in the National Institutes o

88 72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at

89 n-free survival compared with anastrozole in postmenopausal patients who had not received previous en

90 rally) be considered as adjuvant therapy for postmenopausal patients with breast cancer who are deeme

91 ng subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ.

92 ne Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinic

93 le-blind, placebo-controlled, phase 3 trial, postmenopausal patients with early hormone receptor-posi

94 domised, controlled, phase 3 trial, included postmenopausal patients with early-stage hormone recepto

95 cheme of tamoxifen followed by exemestane in postmenopausal patients with early-stage, hormone recept

96 of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -posi

97 ble options as adjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive e

98 icacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive

99 duce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer

100 nce and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms r

101 The postmenopausal period in women is associated with decrea

102 From early postnatal periods until the postmenopausal phase, exposure to over nutrition, high-e

103 Postmenopausal (PM) women with hormone receptor (HR)-pos

104 At baseline, E2 was above the postmenopausal range (>10 pg/mL) in 28 of 76 women (37%)

105 hecked and returned at 16 pg/mL (61 pmol/L); postmenopausal range for sensitive assay is less than 15

106 factors were strong predictors of levels of postmenopausal risk factors.

107 ant cyclophosphamide-based chemotherapy, had postmenopausal serum estradiol (E2), and had received ta

108 ing AngII administered (14 days) during the "postmenopausal" stage of accelerated ovarian failure (AO

109 Duration of estrogen deficiency in postmenopausal state confers fibrosis risk among postmen

110 Whether duration of estrogen deficiency in postmenopausal state dictates an individual's fibrosis r

111 Postmenopausal status coincides with increased risks for

112 Compared with premenopausal status, postmenopausal status is associated with higher morbidit

113 enrolled women aged 18 years and older with postmenopausal status who had histologically or cytologi

114 Severity of hepatic fibrosis is greater in postmenopausal than in premenopausal women, perhaps owin

115 A healthy 56-year-old postmenopausal woman discovered a palpable mass at the o

116 A 52-year-old postmenopausal woman presented with a palpable mass of t

117 A 60-year-old postmenopausal woman presented with abdominal pain.

118 A 68-year-old postmenopausal woman was diagnosed with breast cancer 6

119 D deficiency in a 55-year-old, asymptomatic, postmenopausal woman.

120 e concentrations were measured in 80 men and postmenopausal women (48 men, 32 women, age 40-65 y) enr

121 tion between MHT and risk of FI among 55,828 postmenopausal women (mean age, 73 years) who participat

122 cases of invasive breast cancer developed in postmenopausal women (n = 121,700) in the Nurses' Health

123 Patients and Methods Postmenopausal women (N = 36,794) ages 50 to 79 years at

124 n (YM), young women (YW), older men (OM) and postmenopausal women (PMW); and (2) measured changes in

125 group analyses revealed that high-performing postmenopausal women (relative to low and middle perform

126 A total of 2303 healthy postmenopausal women 55 years or older were randomized,

127 associations were particularly strong among postmenopausal women [ (CI: 0.57, 0.93) and (CI: 0.74, 0

128 eding trial that was conducted in 81 men and postmenopausal women [49 men and 32 women; age range: 40

129 onsuming a Western-style diet, 49 men and 32 postmenopausal women [age range: 40-65 y, body mass inde

130 A total of 439 overweight/obese, healthy, postmenopausal women [body mass index (BMI) > 25 kg/m(2)

131 ion, and invasive breast cancer among 12,701 postmenopausal women aged >/=50 years in a Women's Healt

132 Postmenopausal women aged 18 years or older with histolo

133 Postmenopausal women aged 18 years or older with histolo

134 cebo-controlled, phase 2 study, we recruited postmenopausal women aged 18 years or older with oestrog

135 Observational follow-up of US multiethnic postmenopausal women aged 50 to 79 years enrolled in 2 r

136 A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled a

137 is randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in

138 fication Trial.Participants comprised 48,835 postmenopausal women aged 50-79 y; 40% were randomly ass

139 A total of 67,130 postmenopausal women aged 50-79 years were followed for

140 on microsimulation model of osteoporosis for postmenopausal women aged 55 years or older was develope

141 , placebo-controlled, phase 3 FREEDOM trial, postmenopausal women aged 60-90 years with osteoporosis

142 METHODS AND Data of 1023 postmenopausal women and 1124 men (>/=45 years) with car

143 BC count was measured at baseline in 160,117 postmenopausal women and again in year 3 in 74,375 parti

144 alent risk factor for both premenopausal and postmenopausal women and had the largest effect on the P

145 ctive strategy for osteoporosis screening in postmenopausal women and has the potential to prevent a

146 In contrast, postmenopausal women and men showed consistently low lev

147 for the prevention of chronic conditions in postmenopausal women and whether outcomes vary among wom

148 tion is associated with lower rates of HF in postmenopausal women and whether the effects differ betw

149 baseline hemoglobin was measured in 160,081 postmenopausal women and year 3 hemoglobin was measured

150 cholesterol-lowering medications.CVD risk in postmenopausal women appears to be sensitive to a change

151 he present study, self-reported intakes from postmenopausal women at 40 participating US clinical cen

152 tive recruited a large prospective cohort of postmenopausal women between 1993 and 1998.

153 for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%.

154 range of potential nutritional biomarkers in postmenopausal women by using a controlled feeding study

155 tary pattern on the cardiovascular health of postmenopausal women continues to be of public health in

156 cent to the fracture site were obtained from postmenopausal women during fracture repair surgery (fra

157 th a total of 58146 premenopausal and 144600 postmenopausal women enrolled in the study.

158 We prospectively examined a cohort of 93,676 postmenopausal women enrolled in the Women's Health Init

159 and HFrEF in a multiracial cohort of 42 170 postmenopausal women followed up for a mean of 13.2 year

160 h 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries an

161 Postmenopausal women from the Women's Health Initiative

162 The study population comprised 51,754 postmenopausal women from the Women's Health Initiative

163 (CaD) and fracture risk.Data from 5823 white postmenopausal women from the Women's Health Initiative

164 alized controlled feeding study in which 153 postmenopausal women from the Women's Health Initiative

165 In women with benign tissue, postmenopausal women had a higher PUFA (0.35 +/- 0.06 vs

166 ent bladder cancers among a cohort of 34,708 postmenopausal women in Iowa (1986-2010).

167 king water and diet and bladder cancer among postmenopausal women in Iowa.

168 d with a modestly increased risk of FI among postmenopausal women in the Nurses' Health Study.

169 A total of 1 312 051 postmenopausal women in the UK Million Women Study, aged

170 blood pressure and incident hypertension in postmenopausal women in the Women's Health Initiative Ob

171 acid fractions in breast adipose tissue for postmenopausal women in whom BMI values are not correlat

172 Of 74,750 postmenopausal women included in the study, 3,612 develo

173 Conclusion Intentional weight loss in postmenopausal women is associated with a lower endometr

174 Estrogen-alone therapy in postmenopausal women is associated with a small but sign

175 one therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, t

176 of weight loss on endometrial cancer risk in postmenopausal women is limited.

177 benefits and the harms of hormone therapy in postmenopausal women is small to moderate.

178 findings of higher E2 levels in men than in postmenopausal women may suggest that decreased oestroge

179 Conclusion In our observational cohort of postmenopausal women observed from 2004 to 2011, BP use,

180 We enrolled postmenopausal women of any age with hormone receptor-po

181 Data of 3,117 postmenopausal women participants of the Rotterdam Study

182 Methods The study population included 64,438 postmenopausal women participating in the French E3N (Et

183 orectomy (BSO), and incidence of diabetes in postmenopausal women participating in the Women's Health

184 nd risk of colorectal cancer (CRC) in 87,042 postmenopausal women recruited from 1993-1998 by the Wom

185 ongitudinal prospective cohort evaluation of postmenopausal women recruited from 40 clinical centers.

186 The study that involved postmenopausal women showed a wide range of porosity ind

187 Postmenopausal women showed enhanced bilateral hippocamp

188 The relative preponderance among postmenopausal women suggests that estrogen deprivation

189 With this strategy, 12.8% of postmenopausal women sustained hip fractures in their re

190 le-blinded trial was performed in 14 healthy postmenopausal women to compare doses of 0, 10, and 20 g

191 CI of 2-year increments) with depression in postmenopausal women was shown for increasing age at men

192 A total of 643 healthy postmenopausal women were stratified according to time s

193 l health and evaluate salivary biomarkers in postmenopausal women who are survivors of early-stage (I

194 Treatment is generally recommended in postmenopausal women who have a bone mineral density T s

195 ry prevention of chronic conditions for most postmenopausal women who have had a hysterectomy.

196 primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy.

197 lth Initiative RA Study (1993-2010), sampled postmenopausal women who reported RA at baseline (1993-1

198 blood pressures at annual visit 3 in 29,985 postmenopausal women who were not hypertensive at baseli

199 Data from 488 postmenopausal women with (1) histologic diagnosis of no

200 The study enrolled postmenopausal women with a diagnosis of MBC and prior e

201 The Task Force concluded that postmenopausal women with an estimated 5-year risk for b

202 ry prevention of chronic conditions for most postmenopausal women with an intact uterus and that estr

203 and Participants: A retrospective cohort of postmenopausal women with breast cancer diagnosed from J

204 4747 (89.8%) premenopausal and 12502 (95.1%) postmenopausal women with breast cancer had at least 1 b

205 arotid plaque composition in elderly men and postmenopausal women with carotid atherosclerosis, as we

206 KD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials).

207 Participants were postmenopausal women with clinically detected node-negat

208 l to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ under

209 e-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and

210 -blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-

211 bined with endocrine therapy is effective in postmenopausal women with endocrine-resistant, hormone r

212 We used multimodal imaging to compare 26 postmenopausal women with fibromyalgia with 25 healthy c

213 A total of 13273 postmenopausal women with hormone receptor-positive brea

214 INTERPRETATION: In postmenopausal women with hormone receptor-positive brea

215 ble-blind trial that randomly assigned 6,193 postmenopausal women with hormone receptor-positive earl

216 Postmenopausal women with hormone-positive ductal carcin

217 Postmenopausal women with hormone-positive ductal carcin

218 strozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS

219 acy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS

220 than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive inva

221 Methods Postmenopausal women with HR-positive and node-positive

222 ase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast ca

223 th letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative rec

224 limus may be administered with exemestane to postmenopausal women with MBC whose disease progresses w

225 this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estro

226 to hormone therapy (n = 26) and asymptomatic postmenopausal women with no history of depression (n =

227 menopausal state confers fibrosis risk among postmenopausal women with nonalcoholic fatty liver disea

228 ime from menopause with fibrosis severity in postmenopausal women with nonalcoholic fatty liver disea

229 Postmenopausal women with nonalcoholic steatohepatitis a

230 d Methods The trial randomly assigned 48,835 postmenopausal women with normal mammograms and without

231 lpha-OH), and stimulated equol production in postmenopausal women with osteopenia.

232 We enrolled 4093 postmenopausal women with osteoporosis and a fragility f

233 In postmenopausal women with osteoporosis who were at high

234 b, which is widely used for the treatment of postmenopausal women with osteoporosis.

235 Participants included asymptomatic postmenopausal women with past PMD responsive to hormone

236 t MUC1 had 2.5 times stronger association in postmenopausal women with progestin use (beta=-0.028, p=

237 ncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (A

238 This cohort (n = 101,504) included postmenopausal women without T2D who completed a baselin

239 Among postmenopausal women, 22.8% (95% CI, 18.3%-27.3%) of bre

240 In previously inactive postmenopausal women, a 1-year prescription of moderate

241 n's Health Initiative (WHI) enrolled 161 809 postmenopausal women, aged 50 to 79 years (mean [SD] age

242 e mortality, and other major endpoints among postmenopausal women, aged 50-79 years at HT initiation.

243 ian cancer incidence is highest in peri- and postmenopausal women, and epidemiological studies have e

244 es of unmedicated naturally ovulating women, postmenopausal women, and men daily and determined urina

245 own whether similar risks exist for recently postmenopausal women, and whether MHT affects mood in yo

246 For postmenopausal women, aromatase inhibitors (AIs) are the

247 In this large prospective cohort of postmenopausal women, bisphosphonate use was associated

248 In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammog

249 However, among postmenopausal women, greater adherence to HEI-2010 (qua

250 Among postmenopausal women, hormone therapy with CEE plus MPA

251 in a very homogeneous population of healthy postmenopausal women, indicate that there is a beneficia

252 nd slightly obese individuals (30 men and 22 postmenopausal women, mean +/- SD age: 62 +/- 6 y) were

253 Results For postmenopausal women, MUFA was lower (0.38 +/- 0.06 vs 0

254 In this multiracial cohort of postmenopausal women, obesity stands out as a significan

255 d 96.7 mg/L in men, premenopausal women, and postmenopausal women, respectively.

256 In postmenopausal women, serum PFOS was negatively associat

257 In postmenopausal women, the corresponding difference in ra

258 iated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy

259 ficantly increased bone calcium retention in postmenopausal women, which improved the bone calcium ba

260 bacterial disease (PNTM) often affects white postmenopausal women, with a tall and lean body habitus

261 d motivate programs for weight loss in obese postmenopausal women.

262 ciated with increased risk of diabetes among postmenopausal women.

263 opausal women and 61.7 (7.2) years among the postmenopausal women.

264 cancer risk factors among premenopausal and postmenopausal women.

265 women and 54.7% (95% CI, 46.5%-54.7%) among postmenopausal women.

266 nondairy, and vegetable origins) in healthy postmenopausal women.

267 higher compared to 13.8 +/- 11.8 pmol/L for postmenopausal women.

268 dence of and mortality by race/ethnicity for postmenopausal women.

269 th an increased risk of bladder cancer among postmenopausal women.

270 ine are not risk factors for hypertension in postmenopausal women.

271 in gallate (EGCG) on blood lipids in healthy postmenopausal women.

272 ted with risk of CRC in this large cohort of postmenopausal women.

273 itable for application in this population of postmenopausal women.

274 LS mortality associated with strenuous PA in postmenopausal women.

275 were inversely associated with T2D in these postmenopausal women.

276 end points in perimenopausal, menopausal, or postmenopausal women.

277 one-receptor-positive early breast cancer in postmenopausal women.

278 to determine the skeletal benefits of SCF in postmenopausal women.

279 servational Study (1993-2012), a US study of postmenopausal women.

280 her risk factors for CTS identified in these postmenopausal women.

281 ism for the increased ovarian cancer risk in postmenopausal women.

282 n on the risk of cancer in a large cohort of postmenopausal women.

283 premenopausal women but an increased risk in postmenopausal women.

284 , non-Hodgkin lymphoma, and breast cancer in postmenopausal women.

285 %, for women with no family history, and for postmenopausal women.

286 sion of the gene encoding NKB is elevated in postmenopausal women.

287 riety of cancers, including breast cancer in postmenopausal women.

288 sociations of ESH and T2D were based only in postmenopausal women.

289 increases the risk of endometrial cancer in postmenopausal women.

290 ial effect on bone turnover markers (BTM) in postmenopausal women.

291 primary prevention of chronic conditions in postmenopausal women.

292 eased breast cancer incidence in a cohort of postmenopausal women.

293 tive as a screening tool for osteoporosis in postmenopausal women.

294 has a negative impact on quality of life of postmenopausal women.

295 itable for application in this population of postmenopausal women.

296 compared with continuous use of letrozole in postmenopausal women.

297 nd 18.4%, 12.7%, and 10.5%, respectively, in postmenopausal women.An interactive program for calculat

298 bone mineral density (BMD) loss in peri- and postmenopausal women.We systematically searched EMBASE a

299 Participants included 58 postmenopausal women: 29 with BCa on AIs and 29 controls

300 (95% CI: 0.91, 1.09) based on 1,172 cases in postmenopausal women; p-interaction=0.08].